loader2
Partner With Us NRI

Dishman Carbogen Amcis Ltd

Company details

82.20
86.05
80.05
202.40
6M Return -30.72%
1Y Return -57.69%
Mkt Cap.(Cr) 1,315.41
Volume 97,503
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 97,503

Open Free Demat Account Online with ICICIDIRECT

Dishman Carbogen Amcis Ltd.

Q1FY23 Quarterly Result Announced for Dishman Carbogen Amcis Ltd.

Pharmaceuticals firm Dishman Carbogen Amcis announced Q1FY23 Result :

  • Net Revenue at Rs 5,406.1 mn in Q1 FY23 down by 1.8% YoY mainly on account of lower revenues from Netherlands business.
  • Dishman Carbogen Amcis - NCE APIs and Intermediates revenue increased by 91.9% YoY primarily due to:
  • Increased supplies of APIs and intermediates from Bavla site driven by successful customer audits.
  • Dishman Carbogen Amcis - Quats and Generics revenue increased by 7.1% YoY primarily due to:
  • Increased demand for these products especially in the exports market driven by exceptional operational performance by Naroda site.
  • Carbogen Amcis - CRAMS revenue increased by 3.0% YoY primarily due to:
  • Higher Development revenue comprising 70% of the total revenue for the quarter.
  • Carbogen Amcis - Cholesterol and Vitamin D analogues revenue decreased by 46.0% YoY primarily due to:
  • Carbogen Amcis BV’s Q1FY22 revenue was almost 38% of the total year’s revenue, thus extremely front ended, which is not the case this year. One of the customers last year had stocked up huge amount of inventory in June quarter.
  • EBITDA Margin at 16.3% in Q1 FY23 compared to 18.3% in Q1 FY22 due to:
  • Higher energy costs and higher raw material costs impacted the cost base significantly in Carbogen Amcis BV in the first quarter as compared to last year same quarter.
  • Higher logistics costs has also impacted the cost base globally.
  • One time FX loss impact approximately Rs. 9.00 crores as part of “Other Expenses”

 

Result PDF

View Other Company Results

FINANCIALS

Sales

Operating Profit

Profit after Tax

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after Tax

PE

Debt/Equity

P BV

COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 5,548.94 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,728.09 -29,609.20
LAST 3M 42,048.80 -31,382.80
LAST 6M 65,127.04 16,114.05
LAST 12M 194,271.06 -118,498.61

NSE Board Meetings Forthcomming

Feb 10, 2023 l NSE Board Meetings Forthcomming

Dishman Carbogen Amcis Limited - Board Meeting

Feb 06, 2023 l NSE Announcement

Dishman Carbogen Amcis to declare Quarterly Result

Feb 04, 2023 l BSE Announcement

Date Action Type Ratio
No data found

INFORMATION

Stock PE (TTM)

0

Promoter Holding

59.32%

Book Value

354.2465

ROCE

0.81%

ROE

0.88%

Description

  • Dishman Carbogen Amcis Ltd. focuses on the research and development of several in-house technologies to manufacture quaternary ammonium compounds and active pharmaceutical ingredients (API). It was founded in 1983, with its headquarters in Ahmedabad, Gujarat. During the June 2022 quarter, the company reported a total income of Rs 546.28 crore, down 4.72% from the previous quarter that ended in March 2022. On 21 October 2022, Dishman Carbogen Amcis Ltd.’s market capitalisation stood at Rs 1,568 crore.

    The company is listed on the Bombay Stock Exchange with the code 540701, and on the National Stock Exchange with the code DCAL.

    Dishman Carbogen Amcis Ltd. manufactures and supplies marketable molecules, such as vitamins and chemicals, speciality chemicals, and disinfectants. The company’s segments include quats, speciality chemicals, vitamin D, bulk drugs, and traded goods. Its first facility was established in 1987 in Naroda, near Ahmedabad. The company has a global presence with multiple manufacturing facilities in India, China, and Europe, serving healthcare, biopharmaceutical, pharmaceutical, and general industries.

    On 30 June 2022, the company’s shareholding pattern represented a 59.32% promoter stake, which belongs to Adimans Technologies LLP, 5.85% FII stake, 6.64% DII stake, and 28.19% public stake. In the June 2022 quarter, mutual fund holdings decreased from 6.75% to 6.54%, and FII holdings increased from 5.50% to 5.85%. The company’s quarterly net sales for June 2022 were Rs 103.61 crore, up 62.12% from Rs 63.91 crore in June 2021.

    Dishman Carbogen Amcis Ltd.’s leadership team comprises Mr Arpit Vyas, Mr Paolo Armanino, Mr Harshil Dalal, Mr Pascal Villemagne, Mr Alan Fischer, Mr Stephan Fritschi, Mr Robert J Eijkman, and Mr Martin Schneider. The auditors are V D Shukla & Co. and Haribhakti & Co. LLP. As of 30 June 2022, the company had a total of 15.68 crore shares outstanding.

    On 21 October 2022, the company’s share price closed at Rs 99.90 on BSE. On NSE, it closed at Rs 100.05. The share price touched a 52-week high of Rs 258.40 and a 52-week low of Rs 90.10. By investing in Dishman Carbogen Amcis Ltd.’s share, investors earned a six-month return of -45.82% and a one-year return of -53.15%.

    The company’s peers include Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Divis Laboratories Ltd.

    https://www.icicidirect.com/stocks/dishman-carbogen-amcis-ltd-share-price

    https://groww.in/stocks/dishman-carbogen-amcis-ltd

    https://imdcal.com/about-us/company-history

    https://www.linkedin.com/company/imdcal/about/

    https://www.moneycontrol.com/india/stockpricequote/miscellaneous/dishmancarbogenamcis/DCA

    https://www.moneycontrol.com/news/business/earnings/dishman-carboge-standalone-june-2022-net-sales-at-rs-103-61-crore-up-62-12-y-o-y-8993961.html

    https://economictimes.indiatimes.com/dishman-carbogen-amcis-ltd/stocks/companyid-22179.cms

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

No Data Found

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 540701
NSE Code : DCAL
Book Closure Date (Month) :
BSE Group : A
ISIN : INE385W01011

ICICIdirect Dishman Carbogen Amcis Ltd FAQ

You can buy Dishman Carbogen Amcis Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dishman Carbogen Amcis Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Feb 08, 2023 04:01 PM the closing price of Dishman Carbogen Amcis Ltd was ₹ 83.90.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Feb 08, 2023 04:01 PM, the market cap of Dishman Carbogen Amcis Ltd stood at ₹ 1,315.41.
The latest PE ratio of Dishman Carbogen Amcis Ltd as of Feb 08, 2023 04:01 PM is 0
The latest PB ratio of Dishman Carbogen Amcis Ltd as of Feb 08, 2023 04:01 PM is 4.22
The 52-week high of Dishman Carbogen Amcis Ltd is ₹ 202.40 while the 52-week low is ₹ 80.05

Download Our App

market app
market app